Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial

Blood

Volumn 116, Issue 14, 2010, Pages 2448-2454

  Lee, Jong Wook ^a   Yoon, Sung Soo ^b   Shen, Zhi Xiang ^c   Ganser, Arnold ^d   Hsu, Hui Chi ^e   Habr, Dany ^f   Domokos, Gabor ^f   Roubert, Bernard ^f   Porter, John B ^g  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN; DEFERASIROX; DEFERIPRONE; FERRITIN; IRON;

ADJUVANT THERAPY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APLASTIC ANEMIA; ARTICLE; CHELATION THERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SCHOOL CHILD; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; UPPER ABDOMINAL PAIN;

EID: 77957735229     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261289     Document Type: Article

References (35)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
2. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93(4):489-492.
3. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001;47-61.
4. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78(6):487-494. (Pubitemid 46753591)
5. Lee JW. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol. 2008;88(1):16-23.
6. Ohnuma K, Toyoda Y, Nishihira H, et al. [Detection of early cardiac dysfunction in patients with transfusion-dependent aplastic anemia and chronic iron overload in childhood: stress-velocity relation as a sensitive index by echocardiography]. Rinsho Ketsueki. 1996;37(9):825-832.
7. Kim KH, Kim JW, Rhee JY, et al. Cost analysis of iron-related complications in a single institute. Korean J Intern Med. 2009;24(1):33-36.
8. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
9. Payne KA, Rofail D, Baladi JF, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25(8):725-742.
10. Mwanda OW, Otieno CF, Abdalla FK. Transfusion haemosiderosis in spite of regular use of desferrioxamine: case report. East Afr Med J. 2004;81(6):326-328.
11. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci. 2008;23(2):320-323.
12. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
13. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462.
14. Min Y, Cheong J, Kim H, et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI [abstract]. Leuk Res. 2009;33(suppl 1):S118-S119. Abstract P102.
15. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
16. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-587.
17. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-287.
18. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518-523. (Pubitemid 351536379)
19. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
20. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
21. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
22. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
23. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-977.
24. Brissot P, Deugnier Y, Cianciulli P, Cairo H, Jeng M, Rabault B. Dose dependent reductions in serum transaminases and ferritin levels correlate during long-term therapy with deferasirox (Exjade, ICL670) [abstract]. Book of Abstracts International BioIron Society. 2007; Abstract 105.
25. Wimazal F, Nosslinger T, Baumgartner C, Sperr WR, Pfeilstocker M, Valent P. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest. 2009;39(5):406-411.
26. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
27. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P. Redox state of glutathione in human plasma. Free Radic Biol Med. 2000;28(4):625-635. (Pubitemid 30136044)
28. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci. 1998;850:191-201.
29. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med. 2008;8(7):609-619.
30. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009;82(6):454-457.
31. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2008;112(11): Abstract 634.
32. Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes [published online ahead of print July 8, 2010]. Leuk Res. doi:10.1016/j.leukres.2010.06.013.
33. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 2010;95(8):1433-1434.
34. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508. (Pubitemid 46046309)
35. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465-476.